Autophagy inducers may be beneficial when there are excess abnormal macromolecules and organelles (Mizushima and Levine, 2020), for example, Rapamycin in breast cancer (Danko et al., 2021); Trastuzumab in HER2 positive breast cancer (Maycotte and Thorburn, 2014); Atorvastatin in prostate cancer (Farrow et al., 2014); Metformin in cervical, breast and endometrial cancer (Lu G. et al., 2021), etc. This evidence concerns the gene ERBB2 and breast cancer.